ACRP Offers DCT Insights
Think tank and survey results inform current DCT landscape.
Two recent activities by ACRP offers insights into industry’s views on decentralized clinical trials (DCT). In a think tank convened in October, participants from a variety of clinical trial stakeholder groups, offered that lack of clarity around regulatory requirements is the leading barrier to adopting DCTs at the site level, as well as a lack of budget flexibility and the challenges of managing third-party vendors. Additionally, survey results released by ACRP revealed that on a site-level, DCT technology utilization lags behind other trial technologies, sites that use DCT elements spend more time on trial delivery activities, and personnel perceptions of DCT elements strongly influence DCT acceptance.
Read more information on these ACRP resources.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FSP Outsourcing in Clinical Research: Trends and Opportunities
June 9th 2025When drug developers choose the right outsourcing strategies in clinical research, they can gain significant benefits in terms of quality, efficiency, and operational success. In its third annual Functional Service Provider (FSP) Trends Report, Thermo Fisher Scientific’s clinical research business—PPD—gathered insights from 150 global biotech and pharma leaders to determine how FSP models help sponsors address common industry obstacles.
